Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy

被引:40
作者
George, L
Bladou, F
Bardou, VJ
Gravis, G
Tallet, A
Alzieu, C
Serment, G
Salem, N
机构
[1] Hop Salvator, Dept Urol, F-13274 Marseille 9, France
[2] Inst J Paoli I Calmettes, Dept Radiotherapy, F-13009 Marseille, France
[3] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
[4] Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France
关键词
D O I
10.1016/j.urology.2004.04.088
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To describe the outcome of patients with muscle-invasive bladder carcinoma treated with multimodality therapy in our institution from 1993 to 2002. Methods. The charts of 60 patients with Stage T2-T4N0-N1M0 treated with transurethral resection of bladder tumor followed by a chemoradiotherapy combination were retrospectively reviewed. Of the 60 patients, 22 had received neoadjuvant chemotherapy (methotrexate, cisplatin, and vinblastine or methotrexate, adriamycin, cisplatin, and vinblastine) followed by concomitant chemoradiotherapy (weekly cisplatin/carboplatin or a cisplatin and 5-fluorouracil combination), and 38 had received concomitant chemoradiotherapy alone. Radiotherapy delivered a median dose of 45 Gy to the pelvis and 65 Gy to the bladder in a once-daily or twice-daily fractionation scheme. Follow-up evaluations included cystoscopy with biopsies at regular intervals. Salvage cystectomy was recommended in the case of local persistent tumor or bladder relapse. Results. The median follow-up was 48.5 months (range 10 to 126). Of the 22 patients who received neoadjuvant chemotherapy, 18 (82%) had received two or more cycles; 51 (85%) of the 60 patients received the concomitant chemotherapy as planned. Radiotherapy was completed in 56 patients. Twenty-eight patients developed relapse either locally (14 did not achieve a complete local response after chemoradiotherapy and 6 had true local relapse during follow-up) or at distant sites. The actuarial 5-year disease-specific survival and freedom from local and distant relapse rate was 54% and 42%, respectively. The actuarial local control rate with an intact bladder was 56% at 5 years. When stratified according to stage and grade, patients with Stage T2-T3, grade 2 tumors had a statistically significantly better chance of remaining relapse free than did the others (P = 0.045). Salvage cystectomy (n = 11) for isolated local failure in this population achieved limited results. Conclusions. Transurethral resection of bladder tumor with this chemoradiotherapy combination achieved satisfactory results in this unfavorable Population with invasive bladder carcinoma.
引用
收藏
页码:488 / 493
页数:6
相关论文
共 29 条
[21]   MUSCLE-INVASIVE BLADDER-CANCER TREATED WITH EXTERNAL-BEAM RADIOTHERAPY - PROGNOSTIC FACTORS [J].
POLLACK, A ;
ZAGARS, GK ;
SWANSON, DA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (02) :267-277
[22]   Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection - A survival analysis focusing on TUR as monotherapy [J].
Roosen, JU ;
Geertsen, U ;
Jahn, H ;
Weinreich, J ;
Nissen, HM .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1997, 31 (01) :39-42
[23]   Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer [J].
Sauer, R ;
Birkenhake, S ;
Kühn, R ;
Wittekind, C ;
Schrott, KM ;
Martus, P .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (01) :121-127
[24]   Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03 [J].
Shipley, WU ;
Winter, KA ;
Kaufman, DS ;
Lee, WR ;
Heney, NM ;
Tester, WR ;
Donnelly, BJ ;
Venner, PM ;
Perez, CA ;
Murray, KJ ;
Doggett, RS ;
True, LD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3576-3583
[25]   Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer [J].
Shipley, WU ;
Kaufman, DS ;
Zehr, E ;
Heney, NM ;
Lane, SC ;
Thakral, HK ;
Althausen, AF ;
Zietman, AL .
UROLOGY, 2002, 60 (01) :62-67
[26]   COMBINED MODALITY PROGRAM WITH POSSIBLE ORGAN PRESERVATION FOR INVASIVE BLADDER-CARCINOMA - RESULTS OF RTOG PROTOCOL 85-12 [J].
TESTER, W ;
PORTER, A ;
ASBELL, S ;
COUGHLIN, C ;
HEANEY, J ;
KRALL, J ;
MARTZ, K ;
VENNER, P ;
HAMMOND, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (05) :783-790
[27]  
Viens P, 1996, EUR CYTOKINE NETW, V7, P395
[28]   Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study [J].
von der Maase, H ;
Hansen, SW ;
Roberts, JT ;
Dogliotti, L ;
Oliver, T ;
Moore, MJ ;
Bodrogi, I ;
Albers, P ;
Knuth, A ;
Lippert, CM ;
Kerbrat, P ;
Rovira, PS ;
Wersall, P ;
Cleall, SP ;
Roychowdhury, DF ;
Tomlin, I ;
Visseren-Grul, CM ;
Conte, PF .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3068-3077